Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$nwbo #dcvax #glioblastoma https://t.co/irjsMCAx1Y
— rj (@sharpie510) April 29, 2024
Hey Luke,I’m so happy for you that your fortunate enough to get the DCVax-L. I was administered it by my renowned Neurosurgeon Dr. Linda Liau who helped create it, in 2015. 9 years Later I’m still here, no tumor recurrence. It seems we dig the same things photo, movies. Take Care
— Thomas Owen McCaffrey (@ThomasOwenMcCa1) April 29, 2024
The return of the king is significant, said George Gross, the founder of the British Coronations Project at King's College London.
— rj (@sharpie510) April 27, 2024
Dr. Ashkan at King's College London is the EU Lead for the #DCVax-L p3 trial.$nwbo #glioblastomahttps://t.co/5nsP48zNjrhttps://t.co/R57fxNvJkO
Meanwhile, Alice got #DCVax-L for metastatic merkel cell carcinoma (2x deadlier than melanoma). Already 6.5 years after receiving her 1st dose of DCVax-L, she tells her story at ASCO 2018. I believe she's still cancer free today. $nwbo
— rj (@sharpie510) April 26, 2024
Go to 36m:25s mark:https://t.co/Cj9xABpucF
To kick off the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, noted 6 major trends in the 2023 specialty therapy pipeline:https://t.co/McgUeOpUJk$nwbo #dcvax #glioblastoma @WalgreensNews @POTUS @FLOTUS @NIHDirector @NCIDirector pic.twitter.com/mpA1U2AuvP
— rj (@sharpie510) April 26, 2024
This is fantastic news! Convenience, cost savings, & reduction in hospital visits for patients.
— rj (@sharpie510) April 26, 2024
👏
The DCVax® Platform For All Solid Tumor Cancers$nwbo #dcvax #glioblastoma @WalgreensNews @POTUS @FLOTUS @NIHDirector @NCIDirectorhttps://t.co/5uzCqiFqWjhttps://t.co/6JnBRLZ3yF
Instead of archaic SOC, why can't he access #DCVax-L for #glioblastoma? Available in UK now, but can't get #CancerVaccine in USA.$nwbo #CancerResearch #ForAllSolidTumors #CancerMoonshot @potus @flotus @nihdirector @ncidirector $mrk $bmy $rhhby $azn $llyhttps://t.co/dpDaNLttb5
— rj (@sharpie510) April 8, 2024
“Tumor lysate-loaded DCs (DCVax-L) have acquired additional T cell stimulatory capacity, resulting in more late generation T cells to fight the tumor” -Marnix Bosch #asco2023 #dcvax $nwbo pic.twitter.com/x6gn4IaQvq
— Allen Turner (@AllenTurner206) June 3, 2023
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) March 3, 2024
Chemotherapy Alters Immune Cell Landscape in Pancreatic Cancer
MARCH 1, 2023
Discovery May Help Explain Immunotherapy Resistance
This article potentially raises some very interesting questions with regards to the future use of Chemotherapy in combination and… pic.twitter.com/Eko9U7XxK3
The paradigm shift begins...
— rj (@sharpie510) April 7, 2024
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪$nwbo #dcvax #glioblastoma #CancerResearch #CancerVaccine #ForAllSolidTumors #CancerMoonshot @potus @flotus @nihdirector @ncidirector $mrk $bmy $rhhby $azn $lly https://t.co/GEgo3sJVZU
TDA/Schwab's ThinkOrSwim app lets you see level 2 for NWBO. The last time I checked Active Trader Pro ~1 year ago, it did not support level 2 for NWBO.
Schwab now charges $6.95 for OTC trades. They probably adopted this from TD Ameritrade when they merged. Fidelity does not charge any commission to buy or sell NWBO or any other OTC stock.
Chemo was billed at $570,000.00 for 10 months before she died. If DCVax can reduce or eliminate chemo, then this paradigm shift, this new standard of care treatment with DCVax, would be much much cheaper and more effective than the current archaic standard of care. Maybe that is why there are so many fudsters out and about trying to kill NWBO and the DCVax platform.
My husband's #GBM SOC, incl surgery = $1M+. But it will recur & there's no SOC for rGBM.
— Lisa🇺🇸🇺🇦 (@LisainNJUSA) March 3, 2024
Along comes #NWBO w/ #DCVAX. With volume, price likely in the 100k ballpark & IT WORKS.
We know BP hates it, but shouldn't HEALTH INSURANCE be stoked for 💰they'll save? Seriously. pic.twitter.com/l0WWgHvVBu
44m:42s, @faulkingtruth on illegal spoofing.
— rj (@sharpie510) March 29, 2024
👏
48m:42s:
"It's not about $mmtlp alone or $amc alone or you know $nwbo alone..."
💪
50m:45s:
"One that's been brought up several times was Northwest Bio and they have a lawsuit..."
🤞#CitadelScandal #APES
💥https://t.co/2rUDzp19wm
Project Orbis specifically will speed up the approval process in each of the participating countries. It just also so happens to be the very countries that NWBO has been going after patents. Hmmmmmmmmmmmmmmmmm
https://g.co/gemini/share/9cab9d5a8b0d
This is why $NWBO has been pursuing patents for #DCVax in IRP & Project Orbis countries:
— rj (@sharpie510) March 10, 2024
FASTER APPROVAL IN ALL OF THEM!
🤞👏💪#glioblastoma #CancerMoonshot @POTUS @FLOTUS $mrk $bmy $rhhby $azn $lly @NIHDirector @NCIDirector https://t.co/Hkt8NkUdsRhttps://t.co/o22ZPqiwpu pic.twitter.com/3wSBQ4wlqq
$NWBO #DCVax-L is awaiting approval, the phase 3 study showed significant improvements in long-term survival. A smaller study combining DCVax-L with immune boosters showed exceptional results. Approval in the UK appears imminent, with approval in the US to follow.💪#glioblastoma https://t.co/ASKA40MYUl
— rj (@sharpie510) March 9, 2024
Today’s FT $NWBO & spoofing! pic.twitter.com/WUphDLODAt
— Richard Fairgrieve (@RichFairgrieve) March 2, 2024
I think this in no way affects the scaling of the EDEN devices. They will always be improving the performance, design and functionality. Perhaps it will make sense in the future to have a single machine processing multiple individual batches, but right now I don't see why they would need to consider that given how small the footprint is for the single batch EDEN they now have. This is a great milestone for Northwest Biotherapeutics and Flaskworks. Being able to fully close, automate, and operate this reliable and inexpensive device (not to mention the process can be repeated in as many devices as needed in lower grade Class C cleanrooms) is something we will all look back on and realize how IMPORTANT this was for the success of the DCVax® franchise. This PR tells everyone they finalized the EDEN device that can be scaled to produce 100s of thousands OR MORE multi-year batches personalized for each patient possible every single year. That would not be possible using the artisan method.
From NIH:
The FDA must make sure that a drug is safe and effective for a specific use. However, it does not control the decision doctors make about which drugs to use for their patients. This means that once the FDA approves a drug, doctors can prescribe it for any purpose they think makes sense for the patient.
Off-label uses may include using an approved drug
for a different type of cancer than the one it is approved to treat
at a different dose or frequency
to treat a child when it is approved to treat adults
Off-label uses of a drug can become approved uses if the company that makes it obtains approval from the FDA. To gain the added approvals, the company must conduct research studies to show that the treatment is safe and effective for the new uses. However, a company may decide not to invest time and money in this research.
https://www.cancer.gov/about-cancer/treatment/drugs/off-label.
Wonderful to hear a #glioblastoma patient can see a path for their life 12 years into the future. Go Tracy!!
— rj (@sharpie510) January 28, 2024
🙏
DCVax-L is the paradigm shift in cancer treatment we've been waiting for.
💪@POTUS @FLOTUS @NCIDirector @NIHDirector $nwbo #dcvax #CancerMoonshot #ForAllSolidTumors https://t.co/ub65uo8cCC pic.twitter.com/l5aWUC2vK4
George Kolasa, Fashion Marketing Executive, died of glioblastoma 7 months after starting his first dose of CeGat.
Correction: George received CeGaT vaccine. Hopeful so many are working to find a cure for #glioblastoma. I cannot wait to see the published results for combo #DCVax-L & Poly-ICLC.$nwbo #ForAllSolidTumors @POTUS #CancerMoonshothttps://t.co/gN6d7UKoB4 https://t.co/4irYDVIbdN pic.twitter.com/zeQEFxhCUf
— rj (@sharpie510) August 11, 2023
You may be right that NWBO may accept a hefty settlement. But what about a shareholder class action lawsuit likely to follow? If some want to settle, yet others want the case to "drag on for years" would shareholders be able to continue? I suppose shareholders could refuse settlement and split themselves from said settlement. I for one would like someone, anyone, (i.e., Bigger?) to bring a lawsuit all the way to the very end to expose whatever wrongdoings occurred, or perhaps exonerate the defendants. 😂 Wouldn't the defendants want the truth to be heard if they are innocent?
I don't think LP sold any of her shares. Are you meaning to say 11 million warrants were exercised and converted to shares in the past 3 weeks? Big difference.
They had 40-45 per month capacity 18 months ago when they completed Phase 1A of the Sawston buildout with 2 manufacturing suites (cleanrooms). Phase 1B was started soon after in 2022 and completed sometime in the last month or so (per latest 10-Q). Does anyone have a link to what Phase 1B has done to increase the capacity from that of Phase 1A? I would guess it has at least more than doubled the 40-45 per month and that would be a low end guess. High end guess would be phase 1B completely finished the Sawston facility so 1000 per month is possible, but that sounds too optimistic. How many phases to complete Sawston are there? Is it just Phase 1A and Phase 1B? Or is there more?
"The Company and Advent are working together to prepare for potential commercial operations. The buildout of Phase 1B of the Sawston facility, which had been under way since last year, has been completed." @AdventBio #DCVax-L #Flaskworks $NWBOhttps://t.co/uodvULjmhN https://t.co/chQPX35CB0 pic.twitter.com/NsbqVIAiPJ
— Henry (@HenryMuney) August 9, 2023
Schwab and TD Ameritrade charge $6.95 for OTC trades. That was the reason I transferred out my shares in TD Ameritrade and put them in Fidelity. Fidelity is $0 commission for trades, including OTC.
We know how devastating this disease is. The track record is clear. Thank you for this report. We need to see #Progress and #Hope for #glioblastoma patients. We are on the cusp of a revolution with $nwbo #DCVax-L.
— rj (@sharpie510) August 1, 2023
🙏🙏🙏🙏🙏🙏https://t.co/WOntlAmMgy
One of the doctors in the report definitely looks like Dr. Heinrich Elinzano. Also, this reporter stated the story is coming out of Providence. Dr. Elinzano works in Providence. This and the fact that when marty stated "I won’t be surprised if this reporter puts a different drug as a breakthrough instead of DCVAX-L.", the reporter, Ted Nesi, replied to marty "prepare to be surprised". If that's not enough for you, all will be laid out on Tuesday.
https://www.lifespan.org/providers/heinrich-elinzano-md
$NWBO
— Mionaer (@Mionaer1) July 29, 2023
It is Dr. Elinzano IMO. pic.twitter.com/P66Ke7yORH
prepare to be surprised
— Ted Nesi (@TedNesi) July 29, 2023
Another great story of a #glioblastoma long term survivor (since 2014).
— rj (@sharpie510) July 13, 2023
🫶
He got #DCVax-L with Dr. Ashkan.
👏
The DCVax® Platform For All Solid Tumor Cancers
💪$nwbo #CancerMoonshot @POTUS @NCIDirector https://t.co/DINQezUJiChttps://t.co/L45NK5zOCNhttps://t.co/0mCwiOUi9e
Glioblastoma patient looking for treatment. Hope he discovers, and is able to obtain DCVax-L.
At the 1:00m mark
"And this thing pops up about glioblastoma, join a webinar Optune. It's a drug called Optune. Not a drug it's a treatment you can see the guy's wearing the thing on his head. There were, like I said, I've ignored anything about this. Well I just, well I'm going to read some of the comments. There was not one positive comment that said that that device saved somebody's life extended their life or anything and I've looked at a lot of comments."
This guy, Michael Poarch, @ItsMikePoarch on twitter says 1000 per month and $2 billion. I think this is a bit over the top at this moment because we are still waiting for Sawston to finish Phase 1b and flaskworks is still TBD.
If you know anyone with Cancer this video is for you. If you've ever wanted to make money in the stock market, this video is for you. If you want to see millions of lives improved all over the world, this video is for you. #nwbo #dcvax #Cancer #CancerResearch pic.twitter.com/W1TAcvrRtU
— Michael Poarch (@ItsMikePoarch) June 27, 2023
Les said 370 specials patients done to date, up from 225 as of 5/10/22 (LP@NYAS)= $ 28 million in revenues. = 90% cash flow =$ 25 million in the past 12 months. = 25% of the burn.
— rj (@sharpie510) June 17, 2023
👇https://t.co/h8gO1Y6UYR
The #DCVax® Platform For All Solid Tumor Cancers
💪$nwbo #glioblastoma pic.twitter.com/uz1yzfoPWI
It may not matter to you but you might want to consider opening an account with Fidelity. TDA charges $6.95 per trade for OTC stocks where at Fidelity it is $0.00.
Thanks for this update. I've linked it to twitter along with that very old fox new story with Dr. Siegel. Funny (well not so funny) how it was removed from the Fox news site here: https://www.foxnews.com/video/2814859046001
but youtube still has a copy. ;)
Happy to hear that Dan from a years ago story on DCVax is still very much alive and prominent at #ASCO23.
— rj (@sharpie510) June 17, 2023
👏👏https://t.co/T8gW1xNL8m
The DCVax® Platform For All Solid Tumor Cancers
💪💪$nwbo #dcvax #CancerMoonshot @potus @ncidirector #glioblastomahttps://t.co/vxTq56uqvL pic.twitter.com/QwRCutvzbt
Les said these were compassionate treatment patients, so they are likely not the ones in the clinical trial using DCVax-L and Poly-ICLC. That and the fact that he said "we get the same statistics with them" indicates they received DCVax-L alone. We know the combo is showing EVEN BETTER RESULTS so all of those patients are in a different and more favorable bucket for the regulators to see.
I think Anne Thompson is speaking for herself, not for others. She is adamant that her reporting is not pay to play.
This is a lie. https://t.co/4MlnXUDvki
— Anne Thompson (@annenbcnews) June 15, 2023
New video on youtube with Jamil Newirth. So glad for him!!!!
Jamil is a long term #glioblastoma survivor thanks to Dr. Liau and DCVax-L. Almost 11 YEARS!!
— rj (@sharpie510) June 14, 2023
👏👏👏👏👏
The DCVax® Platform For All Solid Tumor Cancers$nwbo #dcvax #gbm #cancermoonshot @potus
Against the Odds. Surviving Brain Cancer with Jamil Newirthhttps://t.co/SEIPmiKhBX